Honokiol Inhibits Stemness in Pancreatic Cancer via Downregulating c-Met Expression

Area of Science:

• Oncology
• Cancer Biology
• Molecular Medicine

Background:

• Pancreatic cancer (PC) exhibits high recurrence and metastasis rates, leading to poor patient prognosis.
• Cancer stem cells (CSCs) drive PC occurrence and progression, making them a critical therapeutic target.
• Targeting CSC stemness is a promising strategy to improve therapeutic benefits for PC patients.

Purpose of the Study:

• To elucidate the mechanisms by which Honokiol (HNK) inhibits pancreatic cancer stemness.
• To investigate the role of c-Met in PC progression and its modulation by HNK.
• To evaluate HNK's therapeutic potential against PC in preclinical models.

Main Methods:

• Analysis of c-Met expression in public databases and human PC tissues via immunohistochemistry (IHC).
• In vitro assays (colony and sphere formation) to assess HNK's effect on PC cell proliferation and stemness.
• In vivo studies using a subcutaneous transplanted tumor model in nude mice to evaluate HNK's efficacy.

Main Results:

• Elevated c-Met expression in PC tissues correlated positively with poor prognosis.
• Overexpression of c-Met enhanced PC cell proliferation and stemness.
• HNK treatment reversed c-Met-induced effects and suppressed tumor growth in vivo by downregulating c-Met.

Conclusions:

• HNK effectively reduces pancreatic cancer cell proliferation and stemness by suppressing c-Met overexpression.
• Targeting c-Met with HNK presents a potential therapeutic strategy for pancreatic cancer.
• These findings offer new hope for improving outcomes in pancreatic cancer patients.